Back to Results

Elekta AB ADR (EKTAY)

Featured in Small-Cap Stocks

Elekta AB ADR is a depositary receipt representing common stock of Elekta AB (publ), a Swedish medical technology company listed on OTC Markets. Through its underlying issuer, Elekta develops clinical solutions for cancer and brain disorder treatment across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its portfolio includes systems and software for radiation therapy, stereotactic radiosurgery, brachytherapy, neurosurgery, treatment planning, and oncology workflow management, along with related quality assurance, motion management, training, support, and maintenance services. Founded in 1972 and headquartered in Stockholm, Sweden, Elekta also serves veterinary radiation therapy applications through its broader medical technology platform.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-EKTA.Y
$6.08
28.1% Upside
Undervalued
—
—
—
Fair
—
—
0.15
3.2%
August 27, 2026
-34.1x
2.5x
1.1x
1.841 B
2.373 B
29.2%
81.3%
4.3
-176.7%
-451.6%
Send a message
Valuation • Fair Value

Elekta AB ADR (OTC-EKTA.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for Elekta AB ADR (OTC-EKTA.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$6.08

Estimated upside of 28.1% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$8.81

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

$2.34

Dividend discount model valuation reference.

EPV Fair Value

$5.07

Earnings power value estimate.

Comps Fair Value

$5.97

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Elekta AB ADR (OTC-EKTA.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Elekta AB ADR (OTC-EKTA.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.811 B

Current operating scale indicator.

Revenue Forecast

1.78 B

Forward revenue estimate.

EBITDA

182.7 M

Current operating profitability reference.

EBITDA Forecast

356.1 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Elekta AB ADR (OTC-EKTA.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Elekta AB ADR (OTC-EKTA.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-3.15

No elevated caution signal from this screen.

Altman Z-Score

4.3

Relatively strong balance-sheet zone.

FCF / Net Income

-451.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Elekta AB ADR (OTC-EKTA.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Elekta AB ADR (OTC-EKTA.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 27, 2026

Days to Earnings

37

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

3.2%

Income yield reference.

Upcoming Dividend

0.15

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

-176.7%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Elekta AB ADR (OTC-EKTA.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Elekta AB ADR (OTC-EKTA.Y) Stock Forecast & Technical Outlook

Review Elekta AB ADR (OTC-EKTA.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Elekta AB ADR (OTC-EKTA.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Elekta AB ADR (OTC-EKTA.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Elekta AB ADR (OTC-EKTA.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Elekta AB ADR (OTC-EKTA.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Elekta AB ADR (OTC-EKTA.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Elekta AB ADR (OTC-EKTA.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Elekta AB ADR (OTC-EKTA.Y) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Elekta AB ADR (OTC-EKTA.Y) Stock FAQ

Quick answers about Elekta AB ADR (OTC-EKTA.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$6.08
Estimated upside 28.1%
Valuation Rating
Undervalued
Estimated upside of 28.1%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Elekta AB ADR (OTC-EKTA.Y) is $6.08. This implies an estimated upside of 28.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 28.1% versus the current market price.

An analyst price target for Elekta AB ADR (OTC-EKTA.Y) is not currently available in the latest data file.

The current financial health read for Elekta AB ADR (OTC-EKTA.Y) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Elekta AB ADR (OTC-EKTA.Y) is August 27, 2026.

Based on the current data, dividend yield is 3.2%, upcoming dividend amount is 0.15.

The current P/E ratio listed for Elekta AB ADR (OTC-EKTA.Y) is -34.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Elekta AB ADR is 1.841 B.

The current enterprise value listed for Elekta AB ADR is 2.373 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Elekta AB ADR is OTC-EKTA.Y, and the stock is listed on OTC Markets.

Elekta AB ADR (OTC-EKTA.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Elekta AB ADR is 29.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Elekta AB ADR is 81.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on OTC Markets View more

Essilor International SA (ESLOY) Essilor International SA (ESLOY)
Hoya Corp (HOCPY) Hoya Corp (HOCPY)
Siemens Healthineers AG ADR (SMMNY) Siemens Healthineers AG ADR (SMMNY)
Resmed Inc DRC (RSMDF) Resmed Inc DRC (RSMDF)
Terumo Corp ADR (TRUMY) Terumo Corp ADR (TRUMY)
Straumann Holding AG ADR (SAUHY) Straumann Holding AG ADR (SAUHY)
Sonova Holding AG (SONVY) Sonova Holding AG (SONVY)
Coloplast A (CLPBY) Coloplast A (CLPBY)
Fisher & Paykel Healthcare Ltd (FSPKF) Fisher & Paykel Healthcare Ltd (FSPKF)
Olympus Corp (OLYMY) Olympus Corp (OLYMY)
Demant A/S ADR (WILYY) Demant A/S ADR (WILYY)
Getinge Industrier AB (GNGBY) Getinge Industrier AB (GNGBY)
Sysmex Corp (SSMXY) Sysmex Corp (SSMXY)
ConvaTec Group plc ADR (CNVVY) ConvaTec Group plc ADR (CNVVY)
CochLear Ltd ADR (CHEOY) CochLear Ltd ADR (CHEOY)
Ansell Ltd ADR (ANSLY) Ansell Ltd ADR (ANSLY)
Carl Zeiss Meditec AG ADR (CZMWY) Carl Zeiss Meditec AG ADR (CZMWY)
Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY) Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY)
Nihon Kohden Corp ADR (NHNKY) Nihon Kohden Corp ADR (NHNKY)
Top Glove Corporation Bhd ADR (TGLVY) Top Glove Corporation Bhd ADR (TGLVY)
Cyberdyne Inc ADR (CYBQY) Cyberdyne Inc ADR (CYBQY)
Paxman AB (PXMBF) Paxman AB (PXMBF)
Zomedica Corp (ZOMDF) Zomedica Corp (ZOMDF)
Positron Corp (POSC) Positron Corp (POSC)